Beyond Brexit: What Now for Clinical Supply Services across Europe?
Sponsored by: Catalent Clinical Supply
- Clinical Supply Services
Date: 30 April
Days to go: 23
Time: 3PM London/10AM New York
After three years of Brexit withdrawal negotiations, the UK is officially no longer a member of the European Union. Clinical sponsors with active and planned studies in the EU and UK can be reassured that the UK will remain part of the current trade arrangements, customs union and single market until the end of the transition period on December 31, 2020. Although future change is certain after the transition period ends, clinical sponsors now have a clearer vision of what strategic options are available so that they may continue to run trials in the UK and EU. This panel presentation will explore the early analysis of potential Brexit challenges that sponsors face and the strategic solutions that can support sponsors in a post-Brexit world.
Paul Ingram, PhD,
Global Director, Strategic Development and Innovation, Catalent
Paul’s 25 years career has focused on medical device and pharmaceutical research and development. Paul holds a Ph.D. in pharmaceutical development from Strathclyde University in Glasgow. He has over 15 years of experience in clinical supplies working both in Phase 1 units and trial supplies service companies including Quintiles (Aptuit), Fisher Clinical and Catalent.
Director, Transportation Services, Clinical Supply Services, Catalent
Quality Director, Catalent
Manager, Storage and Distribution, Catalent
Key Learning Objectives
- Understand the current status of Brexit and what is next
- Understand the impact of Brexit on the supply chain and clinical supplies in particular
- Explore strategic options for managing clinical supplies in the UK and Europe
- R&D Management
- Clinical Supply Management
- Clinical Operations
- Supply Chain Operations
- Clinical Logistics
- Procurement & Sourcing
- Clinical Trial Consultants